Stay updated with breaking news from Term Liabilities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Net Income increased 125% to $4.3 million for the quarter ended March 31, 2021 as compared to the corresponding quarter one year ago. Income from Operations increased 58% to $4.1 million for the quarter
First Quarter Highlights: Averaged net production of approximately 1.8 bcfe per day for the quarter, of which 89% was natural gas Adjusted EBITDAX Decreased average well cost (2) to approximately $564 per lateral foot during the quarter, resulting in capital expenditures incurred of $148 million Generated $54 million of free cash flow (1) during the quarter Eliminated all debt maturities until Q2 2024 with the retirement of our Convertible Notes in March 2021 and the redemption of our Senior Notes due 2022 in April 2021 Borrowing base reaffirmed at $1.85 billion in April 2021 Reiterating annu...
Investegate announcements from Minerva Neurosciences, Inc, Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
Message : Required fields Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, improved functional ability, favorable safety profile and limited number of psychotic relapses over one year Pivotal bioequivalence study initiated WALTHAM, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, ...
Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, improved functional ability, favorable safety profile and limited number of psychotic relapses over one year Pivotal bioequivalence study initiated WALTHAM, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company f...